You searched for:"Gustavo Salata Romão"
We found (13) results for your search.Summary
Rev Bras Ginecol Obstet. 2024;46:e-rbgo17
To determine the prevalence of anxiety, depression and burnout in residents of Gynecology and Obstetrics during COVID-19 pandemic in Brazil and its associated factors.
Cross-sectional study involving all regions of Brazil, through the application of a sociodemographic questionnaire, the Hospital Anxiety and Depression Scale (HAD) and the Maslach Burnout Inventory (MBI-HSS) instrument. Multivariate analysis was performed after adjusting the Poisson model.
Among the 719 participating medical residents, screening was positive for anxiety in 75.7% and for depression in 49.8% of cases. Burnout syndrome was evidenced in 41.3% of the physicians studied. Those with depression are more likely to have anxiety (OR 0.797; 95%CI 0.687 - 0.925) and burnout syndrome (OR 0.847 95%CI 0.74 - 0.97). Residents with anxiety (OR 0.805; 95%CI 0.699 - 0.928) and burnout (OR 0.841; 95%CI 0.734 - 0.963) are more likely to have depression.
High prevalence of anxiety, depression and burnout were found in residents of Gynecology and Obstetrics in Brazil, in addition to important correlations between anxiety-depression and depression-burnout.
Summary
Rev Bras Ginecol Obstet. 2019;41(1):01-03
Summary
Rev Bras Ginecol Obstet. 2013;35(3):136-140
DOI 10.1590/S0100-72032013000300008
Anti-mullerian hormone (AMH) is a glycoprotein produced by granulosa cells of primary, pre-antral and small antral ovarian follicles and its clinical applicability has been recently demonstrated by several studies. Prediction of the response to ovarian stimulation for in vitro fertilization corresponds to the most frequent utilization of AMH in clinical practice, being routinely assessed in many services to identify subgroups of women susceptible to a poor response or to Ovarian Hyperstimulation Syndrome. There are great perspectives that AMH may be applicable to the individual determination of risk for iatrogenic gonadal injury in women with neoplasms who will be submitted to chemotherapy. It is also probable that AMH assessment will be included in protocols for the investigation of amenorrhea and oligomenorrhea, since AMH levels are increased in Polycystic Ovary Syndrome, reduced in premature ovarian failure and normal in other conditions such as hyperprolactinemia and hypogonadotropic hypogonadism. It is possible that AMH will be utilized in the future for the prediction of age at menopause and of reproductive prognosis, providing solid bases for pre-conceptive and contraceptive counseling.
Summary
Rev Bras Ginecol Obstet. 2020;42(5):272-288
Summary
Rev Bras Ginecol Obstet. 2010;32(6):279-285
DOI 10.1590/S0100-72032010000600005
PURPOSE: to compare serum markers of oxidative stress between infertile patients with and without endometriosis and to assess the association of these markers with disease staging. METHODS: this was a prospective study conducted on 112 consecutive infertile, non-obese patients younger than 39 years, divided into two groups: Endometriosis (n=48, 26 with minimal and mild endometriosis - Stage I/II, and 22 with moderate and severe endometriosis - Stage III/IV) and Control (n=64, with tubal and/or male factor infertility). Blood samples were collected during the early follicular phase of the menstrual cycle for the analysis of serum malondialdehyde, glutathione and total hydroxyperoxide levels by spectrophotometry and of vitamin E by high performance liquid chromatography. The results were compared between the endometriosis and control groups, stage I/II endometriosis and control, stage III/IV endometriosis and control, and between the two endometriosis subgroups. The level of significance was set at 5% (p<0.05) in all analyses. RESULTS: vitamin E and glutathione levels were lower in the serum of infertile women with moderate/severe endometriosis (21.7±6.0 mMol/L and 159.6±77.2 nMol/g protein, respectively) compared to women with minimal and mild endometriosis (28.3±14.4 mMol/L and 199.6±56.1 nMol/g protein, respectively). Total hydroxyperoxide levels were significantly higher in the endometriosis group (8.9±1.8 µMol/g protein) than in the Control Group (8.0±2 µMol/g protein) and among patients with stage III/IV disease (9.7±2.3 µMol/g protein) compared to patients with stage I/II disease (8.2±1.0 µMol/g protein). No significant differences in serum malondialdehyde levels were observed between groups. CONCLUSIONS: we demonstrated a positive association between infertility related to endometriosis, advanced disease stage and increased serum hydroxyperoxide levels, suggesting an increased production of reactive species in women with endometriosis. These data, taken together with the reduction of serum vitamin E and glutathione levels, suggest the occurrence of systemic oxidative stress in women with infertility associated with endometriosis. The reproductive and metabolic implications of oxidative stress should be assessed in future studies.
Summary
Rev Bras Ginecol Obstet. 2020;42(7):411-414
Summary
Rev Bras Ginecol Obstet. 2021;43(6):425-428
Summary
Rev Bras Ginecol Obstet. 2003;25(8):563-569
DOI 10.1590/S0100-72032003000800004
PURPOSE: to verify the efficacy of a single subcutaneous dose of cetrorelix acetate to avoid premature ovulation in assisted fertilization cycles. METHODS: this is a prospective, controlled and randomized study, with 20 women undergoing ovarian stimulation for assisted fertilization, 10 of whom were submitted to classical GnRH agonist protocol (control group) while 10 utilized a 3-mg subcutaneous dose of the GnRH antagonist on the 7th day of ovarian stimulation (cetrorelix group). Serum FSH, LH, estradiol and progesterone concentrations were assessed on the first, seventh, HCG administration and oocyte retrieval days. Both groups were compared for pituitary suppression (progesterone concentration on HCG day) and assisted fertilization cycle performance (gonadotropin ampoules utilized, follicles over 18 mm, retrieved oocytes, fertilization, implantation and pregnancy rates), utilizing Mann-Whitney and Fisher exact tests. RESULTS: no significant difference was observed between control and cetrorelix groups, respectively, for medians of age (31.5 and 34 years), body mass index (24 and 22), gonadotropin ampoles utilized (34 and 32), follicles over 18 mm (3.5 and 3.3), retrieved oocytes (11 and 5), obtained embryos (4 and 3), fertilization (93,7 and 60%, p=0.07) and pregnancy rates (50 and 60%, p=0.07). Efficient pituitary blockade through the ovarian stimulation period was observed for both groups. CONCLUSIONS: these results confirm the efficacy of a 3-mg dose of cetrorelix acetate to prevent premature ovulation in patients undergoing assisted fertilization and suggest a tendency towards a smaller number of embryos and fertilization rates in the cetrorelix group than in the control group. Implantation and pregnancy rates were similar between groups. Other prospective studies with a greater number of patients should be performed to confirm these results.